REG - Renalytix PLC - Result of AGM

RenalytixAnnouncement

19/12/2024 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241219:nRSS7887Qa&default-theme=true

RNS Number : 7887Q  Renalytix PLC  19 December 2024

Renalytix plc

("Renalytix" or the "Company")

 

Result of AGM

 

LONDON and NEW YORK, 19 December 2024 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), which is commercialising the only FDA-approved and Medicare reimbursed
prognostic test to support early-stage risk assessment for chronic kidney
disease, announces that at the Annual General Meeting ("AGM") held earlier
today, all resolutions were duly passed.

 

The results of the AGM are detailed below:

 

                                                                             For          % voted in favour    Against     % voted against    Withheld
 Ordinary resolutions
 1 Receive and adopt the UK 2024 Annual Report                              215,649,238  99.86%               298,365     0.14%              40,760
 2 Approve Directors' Remuneration Report                                   187,117,898  86.76%               28,544,007  13.24%             326,458
 3 Ratify the selection of CohnReznick                                      215,624,372  99.92%               178,413     0.08%              185,578
 4 Reappoint PKF Littlejohn LLP as Auditors                                 215,760,810  99.91%               184,281     0.09%              43,272
 5 Authorise Board to determine auditors' remuneration                      215,474,022  99.86%               302,821     0.14%              211,520
 6 Authorise the issue of shares under the 2020 Equity Incentive Plan with  151,371,930  83.99%               28,863,246  16.01%             35,753,187
 Non-Employee Sub-Plan
 7 Authorise the Issue of Equity                                            151,554,272  83.99%               28,898,602  16.01%             35,535,489

 Special resolutions
 8 Authorise Issue of Equity without Pre-emptive Rights                     151,648,214  84.04%               28,799,536  15.96%             35,540,613
 9 Authorise Market Purchase of Ordinary Shares                             180,179,511  99.83%               305,940     0.17%              35,502,912

 

 

For further information, please contact:

 

 Renalytix plc                                www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                        Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)  Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker)                Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                          Tel: 020 7933 8780 or renalytix@walbrookpr.com
 Paul McManus / Alice Woodings                Mob: 07980 541 893 / 07407 804 654

 CapComm Partners
 Peter DeNardo                                Tel: 415-389-6400 or investors@renalytix.com

 

 

About Renalytix (www.renalytix.com (http://www.renalytix.com) )

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 10,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBBBDDDBBDGSC